



## **ACADIA Pharmaceuticals to Present at the BIO CEO & Investor Conference on February 13, 2007**

February 6, 2007

SAN DIEGO--(BUSINESS WIRE)--Feb. 6, 2007--ACADIA Pharmaceuticals Inc. (Nasdaq:ACAD), a biopharmaceutical company utilizing innovative technology to fuel drug discovery and clinical development of novel treatments for central nervous system disorders, today announced that it will present at the BIO CEO & Investor Conference 2007 on Tuesday, February 13, 2007, at 11:15 a.m. Eastern Time at The Waldorf=Astoria Hotel in New York City.

A live webcast of ACADIA's presentation will be accessible on the company's website, [www.acadia-pharm.com](http://www.acadia-pharm.com), under the investors section and an archived recording will be available on the website through February 27, 2007.

### **About ACADIA Pharmaceuticals**

ACADIA is a biopharmaceutical company utilizing innovative technology to fuel drug discovery and clinical development of novel treatments for central nervous system disorders. ACADIA currently has five clinical programs as well as a portfolio of preclinical and discovery assets directed at large unmet medical needs, including schizophrenia, Parkinson's disease psychosis, sleep maintenance insomnia, and neuropathic pain. All of the drug candidates in ACADIA's product pipeline emanate from discoveries made using its proprietary drug discovery platform. ACADIA's corporate headquarters is located in San Diego, California and it maintains research and development operations in both San Diego and Malmo, Sweden.

CONTACT: ACADIA Pharmaceuticals Inc.

Lisa Barthelemy, Director, Investor Relations

Thomas H. Aasen, Vice President and Chief Financial Officer

858-558-2871

SOURCE: ACADIA Pharmaceuticals Inc.